anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention belongs to the field of medicine and pharmacology, and is Pharmaceuticals oral granule. The Aceclofenac granule is made by raw material drug aceclofenac, findings and disintegrant. The Aceclofenac granule is phenyl acetic acid non-steroidal anti-inflammatory agent. It has notable anti-inflammatory, analgesic and antipyretic effect. It applies to the treatment of various rheumatoid arthritis, atrophic arthritis, osteoarthritis and spondylitis. It is fit for pain and fever caused by various diseases, and the toxic and side effects is lower than other varieties. Aceclofenac has not granule in prior medicine market; it is innovative formula and benefit for absorbing drug to getting better curative effect and better taste. It is safe, reliable and new drug for treatment of acute, chronic pain and anti-inflammation.
All participants enrolled in the single-arm, open-label extension of the study will receive tecovirimat capsules administered orally for 14 days plus SOC. Number of capsules and frequency of dosage will continue to be based on participant weight.
Each subject in this study received on-demand treatment with recombinant human activated coagulation factor VII for injection for 24 weeks. The single dose for each bleeding event was 90 μg/kg, and the number of doses was increased according to the remission after treatment.
This study was to select 200 patients with advanced tumors with an estimated survival of ≥ 2 months. 50 patients were randomly assigned to each group. The patients were divided into chemotherapy group, chemotherapy combined with thalidomide and megestrol acetate group, The best supportive treatment group, the best supportive treatment combined with thalidomide and megestrol acetate group. The chemotherapy group and the best supportive treatment group were the control group. The combined group was administered continuously for 8 weeks according to thalidomide 100 mg qn po and megestrol acetate 0.16 qd po. Calculating the sum of the longest diameters of the target lesions from each patient before and 8 week after treatment. Patients in each group before treatment, 4th week, and 7th week were observed T cell subsets, B cell subsets, NK cell subsets and the expression of inflammatory cytokines. Through nutritional assessment Table (PG-SGA), Multidimensional Deficit Power Meter (MFSI-SF), Quality of Life Assessment Scale (EORTC QLQ-C30), Prognostic Assessment Form (GPS), Physical Status Assessment Form (ECOG) and lean body mass, upper arm muscle circumference and upper arm muscle area analysis of the effect of thalidomide combined with megestrol acetate on the nutritional status of patients with advanced cancer which reveal that thalidomide combined with megestrol acetate may improve the immune regulation and nutritional status of patients with advanced malignant tumors mechanism.
TREXIMET is contraindicated in patients who have had allergic reactions to prescription as well as to over-the-counter products containing naproxen. It is also contraindicated in patients in whom aspirin or other nonsteroidal anti-inflammatory/analgesic drugs induce the syndrome of asthma, rhinitis, and nasal polyps. Anaphylactic/anaphylactoid reactions to naproxen, whether of the true allergic type or the pharmacologic idiosyncratic type (e.g., aspirin hypersensitivity syndrome), usually but not always occur in patients with a known history of such reactions. Both types of reactions have the potential of being fatal. Therefore, careful questioning of patients for medical conditions such as asthma, nasal polyps, urticaria, and hypotension associated with NSAIDs before starting therapy is important. In addition, if such symptoms occur during therapy, treatment should be discontinued (see WARNINGS: Anaphylactic/Anaphylactoid Reactions and PRECAUTIONS: Preexisting Asthma).
Soccer is a laterally dominant sport owing to the repetitive nature of unilateral kicking. The relationship between functional and body composition asymmetries related to limb dominance in soccer players has yet to be established. When present, asymmetries can increase the risk of injury and low back pain. Our study investigated whether lateral dominance is associated with limb asymmetries in a comprehensive body composition assessment among varsity soccer players. Twenty-seven varsity soccer players (age 20.4 ± 1.7 years old; BMI 22.6 ± 4.6 kg/m2) participated in this study. Body composition was assessed through dual-energy X-ray absorptiometry scans. Results showed low lower limb asymmetry indices in both males (3.82%) and females (3.36%) compared to normal ranges. However, upper limb lean mass exhibited high asymmetry, surpassing thresholds in males (7.3%) and females (4.39%). Significant differences were found in total bone mass among males and total lean body mass among females. Male players exhibited higher asymmetry indices in both arm and trunk mass compared to females. Despite these asymmetries, no significant correlations were found between asymmetry indices and occurrences of lower limb injury or low back pain. The study suggests that while evaluating body composition for injury prevention in soccer shows potential, lateral dominance may be influenced by factors extending beyond sport-specific adaptations.
Preprocedural predictors of treatment efficacy will be useful for excluding in advance patients who would not benefit from this treatment, thereby contributing to improved overall clinical outcomes. During ablathermy treatment lost of energy depend of tissue perfusion and thermic diffusion while energy laying depend of tissue absorption coefficient. Study these parameters before treatment could bring important information to the treatment difficulty and its efficacy. The investigators will study and compare fibroid perfusion with dynamic contrast-enhanced magnetic resonance imaging and contrast-enhanced ultrasound (CEUS). CEUS will be performed with contrast agent (SONOVUE). Thermic diffusion could be linked with fibroid stiffness. Fibroid stiffness will be quantified with velocity of shear wave measured by acoustic radiation force impulse (ARFI). Tissue absorption coefficient is correlated with the architecture and the cellularity of the tissue so the investigators think that apparent diffusion coefficient (computed with diffusion weighted imaging) could be correlated with ablathermy efficiency and other intra procedural thermal parameters.
The scope of work outlined in this proposal will investigate experimentally manipulated social status on acute eating behavior, energy intake, and risk for obesity. This will be accomplished using a randomized, crossover design to place young adults in experimental high and low social status conditions. At visit 1, participants will complete baseline measurements, and then consume a standardized breakfast. In order to control for the influence of stress on eating behavior in both conditions, the participants will participate in the Stroop Test, a test known to induce stress in individuals, following breakfast. Using a computerized randomization scheme, each participant will be randomized to either the low or high social status condition (½ will receive high first; ½ will receive low first) and will receive the packet of rules and instructions for their respective condition. The participants will play Monopoly for up to 2 hours with another player they have not previously met. At the end of the game, the high social status player will be told that they won, and the low social status player will be told that they lost. The participants will participate in the Stroop Test again. Then the investigators will take the players into the Children's Eating Laboratory, where a buffet ad libitum lunch will be served in separate rooms. The participants will have 30 minutes to consume their lunch and plate waste will be measured to assess each participant's dietary intake. There will be a 4-week washout period and the second visit will be exactly like the first, except that they will participate in the alternate social status condition. The investigators will evaluate whether there was within-subject variation in dietary intakes based upon which social status condition they were placed in.
Compounds useful as probes for determining the relative number and/or function of specific receptor subtypes. Of particular interest are nicotinic agonists and antagonists (e.g., metanicotine-type compounds and azaadamantane-type compounds) that are selective to certain nicotinic receptor subtypes. Those compounds are labeled with a radioactive isotopic moiety such as ?11C, 18F, 76Br, 123I or 125¿I. Central nervous system disorders are diagnosed by administering to a patient a detectably labeled compound, and detecting the binding of that compound to selected nicotinic receptor subtypes (e.g., alpha 7 and/or alpha 4 beta 2 receptor subtypes). The compounds that have been administered are detected using methods such as position emission topography (PET) and single-photon emission computed tomography (SPECT). The present invention is useful in the diagnosis of a wide variety of CNS diseases and disorders, including Alzheimer's disease, Parkinson's disease and schizophrenia.
Antimicrobial peptides represent a relatively new discovery in the immune system pathway. Recent designs of synthetically engineered antimicrobial peptides have demonstrated increased potency and efficacy/tolerability, enhanced specificity, and reduced toxicity in comparison. One such peptide, XYLENTRA®, has shown/demonstrated significant promise from significant in vitro studies against a large + pathogens. Additionally, extensive animal studies have shown that the XYLENTRA® is an antimicrobial peptide against a large number of pathogens. The XYLENTRA® peptide is also solute resistant. The peptide XYLENTRA® has shown/demonstrated significant antibacterial activity on test organisms  Staphylococcus aureus  MTCC 96 and  Pseudomonas aeruginosa . MTCC741. A substantial decrease in the microbial population level was observed in animals treated with peptide using the protocol described in detail in the application.
The overarching objective is to develop and evaluate a collaborative, multi-dimensional and culturally tailored community-based model of integrated perinatal MH care. The target population is low-income Black/of African descent women with pregnancy-related stress, anxiety, and depression. There are two specific aims: (1) to refine an individualized plan to integrate patient navigation and a culturally adapted cognitive-behavioral (CBT) intervention for low-income Black/of African Descent women designed to increase recruitment and retention within the healthcare community system, and (2) through a two-arm prospective randomized controlled design, women who are subthreshold and threshold risk for prenatal stress, depression and/or anxiety will participate in one of two interventions: (a) existing prenatal intervention (usual care); or (b) patient navigation plus culturally adapted CBT, and peer support groups.

The investigators will screen 1,000 low-income pregnant AA women (18-45 years of age) in their second pregnancy visit with validated tools for stress, anxiety, and depression. A total of 700 study participants will be recruited from urban prenatal care centers in the Washington DC area and will be randomized Usual Care of Intervention conditions above (n=350/condition). Following randomization, participants will participate in a diagnostic interview based on DSM-5 criteria to 'self-select' themselves into 1 of 2 groups (i.e., 'threshold' or 'subthreshold'). Threshold includes women who meet criteria for depression or anxiety based on DSM-5 diagnostic criteria. Subthreshold includes all other women who do not meet DSM criteria). In the intervention arm, participants in the threshold group will receive a 1:1 CBT treatment intervention, and participants in the subthreshold group will receive a group CBT intervention. Both threshold groups will also include patient navigation and participation in a peer support group. Participants will complete standardized health, mental health, and well-being questionnaires during pregnancy at their prenatal site, and up to 12 months after delivery at their well-baby visits, when they also will complete questionnaires about their infants' development and behavior. All infants also will undergo a standardized developmental test at 12 months. Health care utilization and outcomes also will be collected through electronic medical records.
In the left axilla of a formalin-embalmed adult female cross-breed dog, an unusual course of the axillary artery in relation to the brachial plexus was noted. A part of the axillary artery after the origin of the subscapular artery coursed through the loop formed by the contributions of the caudal pectoral and lateral thoracic nerves and then between the median and ulnar nerves. Thus, the common trunk for the latter two nerves was missing. Instead, in the proximal brachium, they communicated with each other in both directions. A communicating branch between the cranial and caudal pectoral nerves forming a nerve loop, ansa pectoralis lacked the axillary artery and was instead traversed by the subscapular artery. This is a variation in the relationship between the axillary artery and brachial plexus in the domestic dog and has not been reported in the literature yet. The axillary artery entrapped by the contributions of the caudal and lateral thoracic nerves may be considered as a risk factor for the neuroarterial compressions with non-specific signs and should be taken into account both in surgery and imaging.
Surgical site infection (SSI) is a common complication after celiotomy in horses, leading to increased morbidity and costs. Increased concern about antibiotic resistance justifies evaluation of alternative preventive approaches, such a Manuka honey which has displayed antimicrobial properties. Pectin-Honey Hydrogels (PHH), composed by Manuka honey and pectin provide a moist wound environment and microbial growth inhibition. The aim of the study was to evaluate the effectiveness of PHHs in preventing SSI in horses subjected to emergency laparotomy. Horses undergoing laparotomy were evaluated. Horses were randomly divided into two groups: Group 1 received PHH application onto the sutured linea alba before skin closure, while Group 2 received no treatment. Horses with postoperative antimicrobial administration or survival of less than 5 days were excluded. The incidence of SSIs was reported as percentages and compared between groups. Out of 44 horses enrolled in the study, only thirty-six were ultimately included. Exclusions occurred either due to death before 5 days postoperatively (2 horses) or the administration of postoperative antimicrobials (6 horses). The median length of hospitalization was 9 days (range 8-14 days). The overall occurrence of SSI was 19.4 %. One out of eighteen horses (5.5 %) in Group 1 and 6 out of 18 (33.3 %) horses in Group 2 developed SSI. Group 2 had an 8.5-fold increased risk of SSI (p = 0.035, OR = 8.5, 95 % CI. 0.9-80.07). No macroscopically visible adverse reactions were associated with PHH. PHH placed at the abdominal incision during surgery was safe and reduced the prevalence of SSI in horses.
The invention relates to a compound preparation which can depress the oxidative stress effectively and quickly. The main ingredients of the preparation are some micromolecule compounds that can remove or help remove the free radicals, regulate endocrine and circular as well as digestive system. There are also some mineral trace elements and other elements that can recover the imbalance of the organism. The medicine is in solid dosage form of which effervescent tablet and effervescent granule are the most popular. The invention also announced the preparative of the medicine. The animal experiment and clinical test have proved that the preparation can depress the oxidative stress and prevent diseases very effectively.
TQB3455 Tablet administered orally once. Then TQB3455 Tablet administered orally, once daily in 28-day cycle after 7 days of first administration.
A coating for an implantable medical device is disclosed. The coating comprises a polymer and an amino acid chemically bonded, attached or conjugated to the polymer. In one embodiment, the coating can include a therapeutic substance. In lieu of bonding the amino acid to the polymer, the amino acid can be chemically bonded to the therapeutic substance or both the substance and the polymer. The amino acid can be polymers and/or oligomers of L-arginine, and copolymers of L-arginine with lysine. The coating can optionally include a nitric oxide donor, such as diazenium diolate type nitric oxide donors, chemically conjugated to the amino acid.
The invention belongs to the field of functions and applications of medicines, and relates to a new application of nabacacine. The invention provides an application of nabacacine in preparing a medicine for preventing liver metastasis of alcohol-related colon cancer. The drug is a drug that protects the normal immune microenvironment of the liver, thereby inhibiting the formation of alcohol-induced pre-metastatic microenvironment. The invention mainly discloses that preventive application of nabacacine can inhibit microenvironment formation before liver metastasis caused by alcohol from animal experiments. The invention proves that the naburoxin can be used for preventing the liver metastasis of the colon cancer. Therefore, the nabacacine can be used for preparing a pre-hepatic metastasis microenvironment formation resistant medicament for preventing the hepatic metastasis of the colon cancer.
Oligosaccharide aromatic glycoside sulfates and physiologically acceptable salts thereof, are disclosed. Further, antiviral agents having these sulfate compounds as the active components, and particularly an antiviral agent, wherein the virus is one which causes AIDS (Acquired Immune Deficiency Syndrome), are disclosed. The active components or the glycoside sulfates, and the salts thereof, are characterized by an oligosaccharide aromatic glycoside sulfate in which the hydrogen of the position-1 hydroxyl group of the terminal sugar of an oligosaccharide is substituted with a specified formula having an alkyl group consisting of 1 to 18 carbons, an oxygen or no oxygen, and an allylene group. The number of constituent monosaccharides in the oligosaccharide portion is preferably within a range of 2 to 20. Further, 10% or more of the remaining hydroxyl groups of the sugar subunits are subjected to sulfated esterification. In addition the antiviral agent exhibits low toxicity and is useful in the treatment of AIDS. Furthermore, an oligosaccharide is also disclosed as described above with the exception that it is the hydrogen atom of the position 1 hydrogen group at the terminal sugar residue which is substituted with the specified formula, also described above. However, in addition the remaining hydroxyl groups of the sugar portion of this oligosaccharide are protected by acyl groups or are present in an unprotected form. Also disclosed is a method for the production of an oligosaccharide aromatic glycoside sulfate synthesized by sulfation using a sulfating agent.
The invention relates to preparation process and production method for an Ophiopogon Japonicus preparation in an integrated new dosage form, comprising raw materials of effective component including (by weight parts) Ophiopogon japonicus 60, Pinellia ternata 9, Panax ginseng (Radix Ginseng) 6, Radix Glycyrrhizae 4, round-shaped rice 6, and Ziziphus jujuba (Fructus Jujubae) 12. The production method includes: supersonic air flow comminution, alcohol/water extraction, ultrasonic pulverization and extraction, water decoction and concentration, supersonic spray-drying, nanometer grinding, high-pressure homogenization, and nanoparticle preparation. The invention utilizes the advantages such as multi-cooperation and multi-target of the nano-carrier coupling technique. The invention can greatly reduce production cost and greatly increase product quality after large-scale production, and enhance the targeting effect and slow-controlled release effect of drug. The preparation can be administered orally and externally in four periods of time according to midnight-noon ebb-flow and human qi and blood flow rule. The preparation may also be prepared into pellicle and transdermal agent, which can be attached to different parts of human body according to midnight-noon ebb-flow and human qi and blood flow rule or be directly absorbed transdermally.
NEW MATERIAL:A compound shown by the formula I (M is H, or lower alkyl; R is straight-chain, branched-chain, 5-9C cyclic alkyl, etc.; X is -CH=CH-, or -CH2CH2-; wavy line is alpha or beta steric configuration bond), its salt or ester. EXAMPLE:(5Z, 13E)9,15-Dihydroxy-10,10,16-trimethyl-11-oxo-prosta-5,13-dien-1-oic acid. USE:An antitumor agent. PREPARATION:A compound shown by the formula II as a starting raw material is converted into a compound shown by the formula III (B is OH-protecting group), reacted with a compound shown by the formula IV, a dimethoxymethyl group at the 3-position is converted into a formyl group, and the compound is reacted with a compound shown by the formula V, to give a compound shown by the formula VI. The compound shown by the formula VI is reduced, OH groups except at the 4-position are protected, the protecting group at the 4-position and the ester residue M are eliminated, the compound is oxidized at the 4- position, the protecting groups except the 4-position are eliminated to give a compound shown by the formula I wherein M=H, and it is further esterified to give a compound wherein M is lower alkyl.
Patients with low-risk stage I grade 2, 3 ovarian immature teratoma or stage I non-seminoma or seminoma MGCTs undergo observation and can transfer to standard risk arm when eligibility criteria are met. Patients with stage I seminoma testicular MGCT undergo observation, and those with residual/recurrent disease are treated at the discretion of their physician. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial.
Targretin gel should be initially applied once every other day for the first week. The application frequency should be increased at weekly intervals to once daily, then twice daily, then three times daily and finally four times daily according to individual lesion tolerance. Generally, patients were able to maintain a dosing frequency of two to four times per day. Most responses were seen at dosing frequencies of two times per day and higher. If application site toxicity occurs, the application frequency can be reduced. Should severe irritation occur, application of drug can be temporarily discontinued for a few days until the symptoms subside. See CONTRAINDICATIONS, Pregnancy. 

Sufficient gel should be applied to cover the lesion with a generous coating. The gel should be allowed to dry before covering with clothing. Because unaffected skin may become irritated, application of the gel to normal skin surrounding the lesions should be avoided. In addition, do not apply the gel near mucosal surfaces of the body.

A response may be seen as soon as four weeks after initiation of therapy but most patients require longer application. With continued application, further benefit may be attained. The longest onset time for the first response among the responders was 392 days based on the Composite Assessment of Index Lesion Severity in the multicenter study. In clinical trials, Targretin gel was applied for up to 172 weeks.

Targretin gel should be continued as long as the patient is deriving benefit.

Occlusive dressings should not be used with Targretin gel.

Targretin gel is a topical therapy and is not intended for systemic use.  
Targretin gel has not been studied in combination with other CTCL therapies.